Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Summary

The objective of this study is to test the hypothesis that liraglutide (commonly known as Victoza) can promote an anti-inflammatory macrophage phenotype in human adipose tissue and blood, thereby reducing localized and systemic inflammation which are risk factors for cardiovascular disease and may contribute to hyperglycemia. This will be done after 4 weeks of treatment during which weight will remain stable, and again after 12 weeks, during which liraglutide-related weight loss occurs.

Timeline

Start

2015-01

Primary completion

2019-09-27

Completion

2019-09-27

Drugs

Indications